News
BVAXF
0.102
-33.79%
-0.052
Weekly Report: what happened at BVAXF last week (0511-0515)?
Weekly Report · 2d ago
Weekly Report: what happened at BVAXF last week (0504-0508)?
Weekly Report · 05/11 09:31
Weekly Report: what happened at BVAXF last week (0427-0501)?
Weekly Report · 05/04 09:31
BioVaxys study shows MVP-S combo boosts immune response in ovarian cancer model
PUBT · 05/01 12:04
Stocks in play: BioVaxys Technology Corp
Barchart · 05/01 09:39
BioVaxys expects late annual, interim filings after audit delay triggers management trade ban
PUBT · 04/28 21:12
BioVaxys PESCO ovarian cancer trial abstract accepted for presentation at ASCO 2026
PUBT · 04/27 12:10
Weekly Report: what happened at BVAXF last week (0420-0424)?
Weekly Report · 04/27 09:31
Stocks in play: BioVaxys Technology Corp
Barchart · 04/27 08:45
Weekly Report: what happened at BVAXF last week (0413-0417)?
Weekly Report · 04/20 09:30
BioVaxys Updates Market on Cease Trade Order and Delayed Filings
TipRanks · 04/13 21:14
BioVaxys faces management cease-trade order after missing annual financial filing deadline
PUBT · 04/13 20:56
Weekly Report: what happened at BVAXF last week (0406-0410)?
Weekly Report · 04/13 09:31
Weekly Report: what happened at BVAXF last week (0330-0403)?
Weekly Report · 04/06 09:32
BioVaxys Updates on Filing Delays as Executives Face Trading Restrictions
TipRanks · 04/01 04:34
BioVaxys misses annual filing deadline, faces management cease-trade order
Reuters · 03/31 21:35
Weekly Report: what happened at BVAXF last week (0323-0327)?
Weekly Report · 03/30 09:32
Weekly Report: what happened at BVAXF last week (0316-0320)?
Weekly Report · 03/23 09:30
BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order
TipRanks · 03/17 21:44
BioVaxys delays filing audited annual financial statements for year ended Oct. 31, 2025
Reuters · 03/17 20:30
More
Webull provides a variety of real-time BVAXF stock news. You can receive the latest news about Biovaxys Technol through multiple platforms. This information may help you make smarter investment decisions.
About BVAXF
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergies, and other immunological diseases. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers and also delivers an innate immune activator and a universal CD4 T cell helper peptide.